title: Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism.
abstract: Activation of metabotropic glutamate receptor subtype 5 (mGlu5) represents a novel strategy for therapeutic intervention into multiple central nervous system disorders, including schizophrenia. Recently, a number of positive allosteric modulators (PAMs) of mGlu5 were discovered to exhibit in vivo efficacy in rodent models of psychosis, including PAMs possessing varying degrees of agonist activity (ago-PAMs), as well as PAMs devoid of agonist activity. However, previous studies revealed that ago-PAMs can induce seizure activity and behavioral convulsions, whereas pure mGlu5 PAMs do not induce these adverse effects. We recently identified a potent and selective mGlu5 PAM, VU0403602, that was efficacious in reversing amphetamine-induced hyperlocomotion in rats. The compound also induced time-dependent seizure activity that was blocked by coadministration of the mGlu5 antagonist, 2-methyl-6-(phenylethynyl) pyridine. Consistent with potential adverse effects induced by ago-PAMs, we found that VU0403602 had significant allosteric agonist activity. Interestingly, inhibition of VU0403602 metabolism in vivo by a pan cytochrome P450 (P450) inactivator completely protected rats from induction of seizures. P450-mediated biotransformation of VU0403602 was discovered to produce another potent ago-PAM metabolite-ligand (M1) of mGlu5. Electrophysiological studies in rat hippocampal slices confirmed agonist activity of both M1 and VU0403602 and revealed that M1 can induce epileptiform activity in a manner consistent with its proconvulsant behavioral effects. Furthermore, unbound brain exposure of M1 was similar to that of the parent compound, VU0403602. These findings indicate that biotransformation of mGlu5 PAMs to active metabolite-ligands may contribute to the epileptogenesis observed after in vivo administration of this class of allosteric receptor modulators.
authors.affiliation: Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6600, USA.
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Bridges
authors.forename: Jerri M
authors.initials: JM
authors.lastname: Rook
authors.forename: Meredith J
authors.initials: MJ
authors.lastname: Noetzel
authors.forename: Ryan D
authors.initials: RD
authors.lastname: Morrison
authors.forename: Ya
authors.initials: Y
authors.lastname: Zhou
authors.forename: Rocco D
authors.initials: RD
authors.lastname: Gogliotti
authors.forename: Paige N
authors.initials: PN
authors.lastname: Vinson
authors.forename: Zixiu
authors.initials: Z
authors.lastname: Xiang
authors.forename: Carrie K
authors.initials: CK
authors.lastname: Jones
authors.forename: Colleen M
authors.initials: CM
authors.lastname: Niswender
authors.forename: Craig W
authors.initials: CW
authors.lastname: Lindsley
authors.forename: Shaun R
authors.initials: SR
authors.lastname: Stauffer
authors.forename: P Jeffrey
authors.initials: PJ
authors.lastname: Conn
authors.forename: J Scott
authors.initials: JS
authors.lastname: Daniels
mesh_terms: D000494:Allosteric Regulation / Q000187:drug effects; D000818:Animals; D001253:Astrocytes / Q000201:enzymology / Q000378:metabolism; D001711:Biotransformation; D002460:Cell Line; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D057809:HEK293 Cells; D006624:Hippocampus / Q000201:enzymology / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D064529:Receptor, Metabotropic Glutamate 5 / Q000378:metabolism*; D012640:Seizures / Q000139:chemically induced* / Q000378:metabolism
chemical_list: D064529:Receptor, Metabotropic Glutamate 5; D003577:Cytochrome P-450 Enzyme System